Ozmosi | Matuzumab Drug Profile
Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Matuzumab

Alternative Names: matuzumab
Clinical Status: Inactive
Latest Update: 2025-10-23
Latest Update Note: News Article

Product Description

Mechanisms of Action: EGFR Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck
Company Location: Eastern America
Company CEO: Robert M. Davis
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Colorectal Cancer|Gastrointestinal Cancer|Esophageal Cancer|Adenocarcinoma

Phase 1: Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer

Trial ID

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Latest Trial Update Date

Data Updated

ACTRN12615001255572p

 2006-7041-83/hah

N/A

Withdrawn

Encephalomyelitis|Chronic Pain

None

NCT00113581

 EMD 72000-024

P1

Completed

Adenocarcinoma|Esophageal Cancer|Gastrointestinal Cancer

2006-05-01

2019-03-21

Treatments

2006-000899-32

 2006-000899-32

P2

Completed

Non-Small-Cell Lung Cancer

2009-06-05

2022-03-12

Treatments

NCT00215644

 MATRIX EG

P2

Completed

Esophageal Cancer|Gastrointestinal Cancer

2008-07-31

2024-11-27

2005-001362-14

 MAURICE

P2

Completed

Colorectal Cancer

2007-10-30

2022-03-12

Treatments

NCT00111839

 EMD 72000-031

P2

Completed

Non-Small-Cell Lung Cancer

2007-07-31

2019-03-22

Treatments

2005-000146-36

 MATRIX E.G.

P2

Completed

Adenocarcinoma|Gastrointestinal Cancer

2007-04-28

2025-07-05

Treatments

2006-000871-13

 2006-000871-13

P2

Completed

Non-Small-Cell Lung Cancer

2006-10-30

2022-03-12

Treatments

Recent News Events

Date

Type

Title

10/23/2025

News Article

 ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference

03/21/2023

PubMed

 New Perspectives for Prosthetic Valve Endocarditis: Impact of Molecular Imaging by FISHseq Diagnostics.

11/15/2022

PubMed

 Pharmacophore-based virtual screening approaches to identify novel molecular candidates against EGFR through comprehensive computational approaches and in-vitro studies.

09/10/2022

PubMed

 Simultaneous Imaging and Therapy Using Epitope-Specific Anti-Epidermal Growth Factor Receptor (EGFR) Antibody Conjugates.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions